Walgreens’ Chief Human Resources Officer, Holly May, is leaving the company to pursue another opportunity. This follows a series of executive exits and layoffs as Walgreens aims to cut at least $1 billion in costs under new CEO Tim Wentworth.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
